Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of $0.82, $0.84 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $396.78 million versus the consensus estimate of $386.05 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.